K2 Principal Fund’s Adverum Biotechnologies ADVM Stock Holding History

K2 Principal Fund’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,039	Closed	-$10K	–	248
2022 Q3	$10K	Sell	1,039 -9,321	-90%	-$122K	﹤0.01%	263
2022 Q2	$124K	Sell	10,360 -16,730	-62%	-$175K	0.01%	239
2022 Q1	$355K	Sell	27,090 -15,004	-36%	-$220K	0.03%	179
2021 Q4	$741K	Sell	42,094 -123,293	-75%	-$2.47M	0.05%	194
2021 Q3	$3.59M	Buy	165,387 +75,556	+84%	+$1.93M	0.29%	96
2021 Q2	$3.14M	Buy	+89,831	New	+$4.84M	0.26%	116

Other funds holding ADVM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

SGL

Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

K2 Principal Fund's ADVM Position: Q4 2022 in Review

K2 Principal Fund sold out of Adverum Biotechnologies (ADVM) in Q4 2022, closing a stake of 1,039 shares — an estimated $10K sold.

K2 Principal Fund first reported a position in ADVM in Q2 2021 and held it in 6 quarters. The position peaked at $3.59M in Q3 2021. 59 funds tracked by Wall St. Rank hold ADVM as of Q4 2022.

K2 Principal Fund reported no remaining Adverum Biotechnologies position as of Q4 2022 after selling out during the quarter.
K2 Principal Fund sold 1,039 Adverum Biotechnologies shares in Q4 2022, an estimated $10K.
K2 Principal Fund first reported a position in Adverum Biotechnologies in Q2 2021 and held it in 6 quarters.
K2 Principal Fund's Adverum Biotechnologies position peaked at $3.59M in Q3 2021.
59 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2022.

Based on K2 Principal Fund's 13F filing for Q4 2022, filed 10 Feb 2023.